

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 October 2000 (05.10.2000)

PCT

(10) International Publication Number
WO 00/58473 A3

(51) International Patent Classification⁷: C12N 15/12,
C07K 14/47, 16/18, G01N 33/566, C12Q 1/68, C12N
15/11, 15/62, A01K 67/027, A61K 38/00

Richard, A. [US/US]; 191 Leete Street, West Haven,
CT 06516 (US). LEACH, Martin [GB/US]; 884 School
Street, Webster, MA 01570 (US).

(21) International Application Number: PCT/US00/08621

(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., One Financial Center, Boston,
MA 02111 (US).

(22) International Filing Date: 31 March 2000 (31.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/127,607 31 March 1999 (31.03.1999) US
60/127,636 2 April 1999 (02.04.1999) US
60/127,728 5 April 1999 (05.04.1999) US
09/540,763 30 March 2000 (30.03.2000) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier applications:

US 60/127,607 (CIP)
Filed on 31 March 1999 (31.03.1999)
US 60/127,636 (CIP)
Filed on 2 April 1999 (02.04.1999)
US 60/127,728 (CIP)
Filed on 5 April 1999 (05.04.1999)
US 09/540,763 (CIP)
Filed on 30 March 2000 (30.03.2000)

Published:

- With international search report.
- Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

(71) Applicant (*for all designated States except US*): CURA-
GEN CORPORATION [US/US]; 555 Long Wharf Drive,
11th Floor, New Haven, CT 06511 (US).

(88) Date of publication of the international search report:
25 January 2001

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SHIMKETS,

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: NUCLEIC ACIDS INCLUDING OPEN READING FRAMES ENCODING POLYPEPTIDES; "ORFX"

(57) Abstract: The present invention provides open reading frames encoding isolated polypeptides, as well as polynucleotides en-
coding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX
polypeptides, polynucleotides or antibodies. The invention additionally provides methods in which the ORFX polypeptide, polynu-
cleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.

WO 00/58473 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/08621

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C07K16/18 G01N33/56 C12Q1/68
C12N15/11 C12N15/62 A01K67/027 A61K38/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N A01K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, MEDLINE, CAB Data, PAJ, EP0-Internal, WPI Data, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	COLE S.T.: "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence." NATURE, vol. 393, 11 June 1998 (1998-06-11), XP002144873 sequence	
A	--- LAMERDIN J.E.: "Sequence analysis of a 3.5 Mb contig in human 19p13.3 containing a serine protease gene cluster." EMEST DATABASE ENTRY, 8 February 1999 (1999-02-08), XP002144874 sequence --- -/--	

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 August 2000

Date of mailing of the international search report

23.11.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hix, R

INTERNATIONAL SEARCH REPORT

at	Application No
1/US	00/08621

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>M.D. ADAMS ET AL.: "The genome sequence of <i>Drosophila melanogaster</i>."</p> <p>SCIENCE, vol. 287, 24 March 2000 (2000-03-24), pages 2185-2195, XP002144875 the whole document</p> <p>-----</p>	6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/08621

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 27 to 32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

claims 1 to 32 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claim : 1 to 32 partially

Isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from a group consisting of SEQ ID NO 2n wherein n is 1, oligonucleotides less than 100 nucleotides in length and comprising at least 6 contiguous nucleotides from the above sequence, polypeptides encoded by said nucleotides, antibodies that bind to said polypeptide, pharmaceutical composition comprising said polypeptide and methods of detection, screening, therapeutic uses involving said polypeptide.

2. Claim : .

Inventions 2 to 3161

claims 1 to 32 partially :

Isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from a group consisting of SEQ ID NO 2n wherein n is 2 to 3161, oligonucleotides less than 100 nucleotides in length and comprising at least 6 contiguous nucleotides from the above sequence, polypeptides encoded by said nucleotides, antibodies that bind to said polypeptide, pharmaceutical composition comprising said polypeptide and methods of detection, screening, therapeutic uses involving said polypeptide.

THIS PAGE BLANK (USPTO)